

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Global Cannabis Applications Corp. (the "Issuer")**

Trading Symbol: **APP**

Number of Outstanding Listed Securities: **166,325,796 (as at December 31, 2020)**

Date: **January 1, 2021**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world's first end-to-end – from patient to regulator – medical cannabis data solution. It uses core technologies: mobile applications, artificial intelligence, regtech, smart databases, and blockchain, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, the Issuer is focused on viral global expansion by providing the best digital experience in the cannabis market.

During the month of December 2020, the Issuer continued with general and corporate operations with no changes to material activities.

2. Provide a general overview and discussion of the activities of management.

During the month of December 2020, management continued to support and control the Issuer's business activities with a focus on creating broader awareness of the Issuer and continued development of product line.

In addition:

On December 1, 2020 the company announced a leading commercial licensor of proprietary blockchain Data and AI technologies to the medical cannabis industry, today outlined its Ethereum 2.0 rollup-centric roadmap, Eth2; continuing its focus on the benefits that Ethereum-truths bring to the Canadian medical cannabis and adult-use markets, which are forecast to grow to CA\$4.1 billion in 2021¹. GCAC is focussed on delivering irrefutable truths using the Ethereum blockchain where it records the efficacy of medical cannabis treatments. GCAC's smartphone app allows consumers, retailers and growers to contribute data for each step in the lifecycle of medical cannabis. These data contributions are then immutably attested-to using GCAC's Ethereum Eth2 technology. However, GCAC's transactions must be paid for in \$ETH, and recently fees started climbing. Although truth is paramount for medical cannabis, any business based on Ethereum must be both inventive and profitable. So, today's Phase 0 launch of Eth2 affirms GCAC's vision and heralds a new era for its participants to continue to collect and store the truth. Medical cannabis growers and retailers pay GCAC an affordable price to have their truths enshrined on a public blockchain. Following on from today's Ethereum Phase 0 announcement will be Phase 1, expected in 2021. Phase 1 allows GCAC's Eth2 rollup-technology to be deployed in order to store its smartphone data attestations on Eth2's sharded chains. GCAC has invested \$5.92m in Ethereum technology² and expects to deliver further commercial benefits and profitability with Ethereum 2.0 Phase 1. GCAC's CEO, Brad Moore "Public blockchains are the ultimate arbiters of truth, this has been demonstrated ever since the advent of Bitcoin. Ethereum, with its smart contract capabilities, is the ideal next gen of blockchain truths. And now, Eth2 is set to revolutionize Ethereum's commercial use cases. Our business model allows our SaaS licensee subscriptions to pay us for storing cannabis-efficacy truths and doing so while we remain profitable. My vision is coming ever closer and our investors are the ones to thank for their belief and trust in getting us here." On October 2, 2020 @VitalikButerin, co-founder and inventor of Ethereum, stated³ that genuine economic value is a key driver for Ethereum economic sustainability, and rollup-centric models have the ability to collect fees from businesses like GCAC when they provide commercial utility. All GCAC contributions to the delivery of high-throughput rollup clients on Ethereum 2.0 and all smartphone derived attestation data is the intellectual property ("IP") of GCAC. Securing GCAC's IP creates an inherent difficulty in replicating, or directly competing with, GCAC's medical cannabis datasets and technology solutions. The company believes this makes GCAC one of the most complete, and exciting, efficacy platforms in the cannabis and blockchain space.

On December 15, 2020, the company announced the launch of Efixii, its medical cannabis efficacy consumer-app; continuing its focus on the benefits that efficacy-truths bring to the Canadian medical cannabis and adult-use markets, which are forecast to grow to CA\$4.1 billion in 2021¹. The new Efixii app provides numerous free services to consumers as well as premium subscription services. Prices start at \$0.99 per month for a single, personalized cannabis efficacy report for a patient. Prices increase for medical cannabis efficacy trend analyses or AI-driven product guidance based on a patient's symptoms. All in-app premium reports are based on the Efixii lifecycle-data that the GCAC platform acquired from cultivators, labs. and consumers. To bring medical cannabis consumption to the next level, GCAC delivers a suite of seed to sale cannabis

lifecycle attestation technologies. The new Efixii app is a consumer view leveraging GCAC's proprietary big-data set. Valuable lifecycle details such as mother plant genomic sequence, and advanced batch-to-batch comparisons, serve to enhance medical cannabis reproducibility and deliver trustworthy efficacy results that patients can rely on when deciding to medicate with cannabis. GCAC's CEO, Brad Moore: "We're excited to break cover and commercially launch Efixii as the premier medical cannabis efficacy platform. Over the last four years, we have established GCAC as one of the most exclusive, results-driven medical cannabis technologies in Canada and beyond. The launch of our new online business will propel our platform to the next level. We are now focussed on an intensive marketing campaign to attract medical cannabis growers so they can provide truthful cannabis lifecycle data to their consumers by using the GCAC suite of technologies. Over the next 12 months, we have set an achievable goal of attracting 10 new growers cultivating 34 million grams of cannabis with an Efixii QR code on each packaged gram. We believe that this means over 110,000 subscribers will have access to better medical cannabis products, creating better patient outcomes." All Efixii medical cannabis efficacy contributions remain the intellectual property ("IP") of GCAC. Securing GCAC's IP creates an inherent difficulty in replicating, or directly competing with, GCAC's medical cannabis datasets and technology solutions. The company believes this makes GCAC one of the most complete and exciting efficacy platforms in the cannabis space.¹

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None to report during the month of December 2020.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None to report during the month of December 2020.

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None to report during the month of December 2020.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None to report during the month of December 2020.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None to report during the month of December 2020.

8. Describe the acquisition of new customers or loss of customers.

None to report during the month of December 2020.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None to report during the month of December 2020.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None to report during the month of December 2020.

11. Report on any labour disputes and resolutions of those disputes, if applicable.

None to report during the month of December 2020.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None to report during the month of December 2020.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None to report during the month of December 2020.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds ⁽¹⁾
Common shares (financing)	8,400,000	Common shares issued in respect to financing at \$0.05 (issued as part of Unit). Total financing proceeds \$420,000	Working capital
Common shares (debt settlement)	3,160,000	Common shares issued in respect to debt settlement at \$0.05 (issued as part of Unit). Total debt settlement \$158,000	Not applicable
Common share purchase warrants	11,920,000	Warrants issued in connection with financing and debt settlement above (issued as part of unit) Each warrant is exercisable	Not applicable

		for a period of 2 years at an exercise price of \$0.10	
Stock options	Nil		Not applicable

(1) State aggregate proceeds and intended allocation of proceeds

15. Provide details of any loans to or by Related Persons.

None to report during the month of December 2020.

16. Provide details of any changes in directors, officers or committee members.

None to report during the month of December 2020.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

Trends and risks, which may impact the Issuer, are detailed in Item 17, Risk Factors, of the Issuer's Form 2A – Listing Statement dated October 16, 2014.

THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.

Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 1, 2020

Bradley Moore
Name of Director or Senior Officer

/s/ Bradley Moore
Signature

Chief Executive Officer, Director
Official Capacity

Issuer Details Name of Issuer Global Cannabis Applications Corp.	For Month End December 31 2020	Date of Report YY/MM/DD 21/01/01
Issuer Address Suite 830, 1100 Melville Street Vancouver, BC V6E 4A6	Issuer Fax No. N/A	Issuer Telephone No. (855) 269-9554
Contact Name Bradley Moore	Contact Position CEO, Director	Contact Telephone No. (855) 269-9554
Contact Email Address info@cannappscorp.com	Web Site Address www.cannappscorp.com	